No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation

Ann Hematol. 2014 Jan;93(1):165-7. doi: 10.1007/s00277-013-1854-6. Epub 2013 Aug 15.

Authors

Hartmut Bertz¹, Kathrin Drognitz, Michael Lübbert

Affiliation

¹ Division of Hematology, Oncology and Stem Cell Transplantation, University Clinic Department of Internal Medicine I, 79106, Freiburg, Germany, [email protected].

PMID: 23949313
DOI: 10.1007/s00277-013-1854-6

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antifungal Agents / administration & dosage
Antifungal Agents / economics
Antifungal Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Laboratory Techniques / economics
Female
Fluconazole / administration & dosage
Fluconazole / economics
Fluconazole / therapeutic use*
Fungemia / diagnosis
Fungemia / economics
Fungemia / epidemiology
Fungemia / prevention & control
Germany / epidemiology
Humans
Leukemia, Myeloid, Acute / complications*
Leukemia, Myeloid, Acute / drug therapy
Male
Middle Aged
Mycoses / diagnosis
Mycoses / economics
Mycoses / epidemiology
Mycoses / etiology
Mycoses / prevention & control*
Prospective Studies
Triazoles / administration & dosage
Triazoles / economics
Triazoles / therapeutic use*
Young Adult

Substances

Antifungal Agents
Triazoles
posaconazole
Fluconazole